Anus Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ANS011 MIFTS: 49	Anus Cancer Categories: Cancer diseases, Gastrointestinal diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Anus Cancer

MalaCards integrated aliases for Anus Cancer:

Name: Anus Cancer ¹² ¹⁵

Anal Cancer ¹² ⁵³ ⁴³

Anus Neoplasms ⁴⁴ ⁷³

Anus Neoplasm ¹² ¹⁵

Malignant Neoplasm of Anus ⁷³

Malignant Anal Tumor ¹²

Cancer of the Anus ⁵³

Neoplasm of Anus ¹²

Anal Carcinoma ⁷³

Anal Neoplasm ¹²

Anal Tumors ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of anus and anal canal

Malignant neoplasm: Anal canal

Malignant neoplasm: Anus, unspecified

External Ids:

Disease Ontology ¹² DOID:14110 DOID:4551

ICD10 ³³ C21.0 C21.1

ICD9CM ³⁵ 154.2 154.3

NCIt ⁵⁰ C7379 C2877

SNOMED-CT ⁶⁸ 93669004 93676009

MeSH ⁴⁴ D001005

UMLS ⁷³ C0153445 C0153446 C0003463 more

Sources

Summaries for Anus Cancer

NIH Rare Diseases : ⁵³ Anal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the anus. Signs and symptoms of the condition include rectal bleeding; a lump in or near the anus; anal pain; itching; changes in bowel habits; and/or swollen lymph nodes. In most cases, the underlying cause of anal cancer is unknown. There appears to be a link between anal cancer and the human papillomavirus (HPV) infection. Other risk factors for anal cancer include HIV infection, sexual activity, smoking, and a weakened immune system. The best treatment options for anal cancer depend on many factors including the stage of the condition, the location of the tumor and if there are associated conditions (i.e. HIV) but may include surgery, chemotherapy, and radiation therapy.

MalaCards based summary : Anus Cancer, also known as anal cancer, is related to anal canal adenocarcinoma and anal canal squamous cell carcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Anus Cancer is SERPINB3 (Serpin Family B Member 3). The drugs Gardasil and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include testes, lymph node and skin.

Disease Ontology : ¹² A large intestine cancer that is located in the anus.

MedlinePlus : ⁴³ The anus is where stool leaves your body when you go to the bathroom. It is made up of your outer layers of skin and the end of your large intestine. Anal cancer is a disease in which cancer cells form in the tissues of the anus. Anal cancer is rare. It is more common in smokers and people over 50. You are also at higher risk if you have HPV, have anal sex, or have many sexual partners. Symptoms include bleeding, pain, or lumps in the anal area. Anal itching and discharge can also be signs of anal cancer. Doctors use tests that examine the anus to diagnose anal cancer. They include a physical exam, endoscopy, ultrasound, and biopsy. Treatments include radiation therapy, chemotherapy, and surgery. NIH: National Cancer Institute

Wikipedia : ⁷⁶ Anal cancer is a cancer (malignant tumor) which arises from the anus, the distal opening of the... more...

Sources

Related Diseases for Anus Cancer

Diseases related to Anus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)

#	Related Disease	Score	Top Affiliating Genes
1	anal canal adenocarcinoma	30.4	CDX2 KRT7
2	anal canal squamous cell carcinoma	30.3	CDKN2A KRT5 SERPINB3
3	papilloma	30.0	CDKN2A KRT5 KRT7
4	anal canal carcinoma	30.0	CD6 CDKN2A KRT7 SLC14A2
5	rectal neoplasm	29.5	DCXR KRT7 SLC14A2 SMUG1
6	anus disease	29.3	CDKN2A DCXR SERPINB3 SMUG1
7	hemorrhoid	11.3
8	anus sarcoma	11.0
9	vulva squamous cell carcinoma	10.3	CDKN2A SERPINB3
10	vulval paget's disease	10.2	CDKN2A KRT7
11	adenoid basal cell carcinoma	10.2	CDKN2A KRT7
12	bile duct adenoma	10.2	CDKN2A KRT7
13	endocervical carcinoma	10.2	CDKN2A KRT7
14	bladder carcinoma in situ	10.2	CDKN2A KRT7
15	glycogen-rich clear cell breast carcinoma	10.2	CDKN2A KRT7
16	well-differentiated liposarcoma	10.2	CDKN2A KRT7
17	ovary neuroendocrine neoplasm	10.2	CDX2 KRT7
18	appendix adenocarcinoma	10.2	CDX2 KRT7
19	mucinous adenofibroma	10.2	CDX2 KRT7
20	anus adenocarcinoma	10.2	CDX2 KRT7
21	glandular cystitis	10.2	CDX2 KRT7
22	optic nerve sheath meningioma	10.2	CDKN2A KRT5
23	keratinizing squamous cell carcinoma	10.2	CDKN2A KRT5
24	duodenum adenocarcinoma	10.2	CDX2 KRT7
25	epithelial predominant wilms' tumor	10.2	CDX2 KRT7
26	basaloid squamous cell carcinoma	10.2	CDKN2A KRT7
27	cervical adenosquamous carcinoma	10.2	CDKN2A KRT7
28	ovarian mucinous adenocarcinoma	10.2	CDX2 KRT7
29	thymus adenocarcinoma	10.2	CDX2 KRT7
30	balloon cell malignant melanoma	10.2	KRT5 KRT7
31	appendix disease	10.2	CDX2 KRT7
32	benign breast adenomyoepithelioma	10.2	KRT5 KRT7
33	breast adenomyoepithelioma	10.2	KRT5 KRT7
34	gastric diffuse adenocarcinoma	10.2	CDX2 KRT7
35	ceruminoma	10.2	KRT5 KRT7
36	lymphoepithelioma-like thymic carcinoma	10.2	CDKN2A KRT5
37	bladder adenocarcinoma	10.2	CDX2 KRT7
38	benign mesothelioma	10.2	KRT5 KRT7
39	chronic cystitis	10.2	CDX2 KRT7
40	sensory organ benign neoplasm	10.2	KRT5 KRT7
41	bile duct mucoepidermoid carcinoma	10.2	KRT5 KRT7
42	middle ear adenoma	10.2	KRT5 KRT7
43	mucinous ovarian cystadenoma	10.2	CDX2 KRT7
44	large cell acanthoma	10.2	KRT5 KRT7
45	apocrine sweat gland neoplasm	10.2	KRT5 KRT7
46	ampulla of vater adenocarcinoma	10.2	CDX2 KRT7
47	biliary papillomatosis	10.2	CDX2 KRT7
48	duodenal disease	10.2	CDX2 KRT7
49	malignant biphasic mesothelioma	10.2	KRT5 KRT7
50	ovarian mucinous neoplasm	10.2	CDX2 KRT7

Comorbidity relations with Anus Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis	Deficiency Anemia
Rectal Neoplasm

Graphical network of the top 20 diseases related to Anus Cancer:

Sources

Symptoms & Phenotypes for Anus Cancer

UMLS symptoms related to Anus Cancer:

nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, pruritus ani, gastrointestinal gas

Sources

Drugs & Therapeutics for Anus Cancer

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Gardasil ¹⁸ ⁴⁹	quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine	Merck	June 2006
FDA Label: Gardasil Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus Indications and Usage: ¹⁸ GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: humoral immune response Action: inducer FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Anus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Oxaliplatin

Approved, Investigational

Phase 4,Phase 2,Phase 1

61825-94-3

43805 6857599 5310940 9887054

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunoglobulins

Phase 4,Phase 2,Phase 1

Antibodies

Phase 4,Phase 2,Phase 1

Vaccines

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Cola

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Liver Extracts

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 4,Not Applicable

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Early Phase 1

51-21-8

3385

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Octreotide

Approved, Investigational

Phase 3

83150-76-9

383414 6400441

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

Imiquimod

Approved, Investigational

Phase 3

99011-02-6

57469

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Early Phase 1

Anesthetics

Phase 3,Phase 1,Not Applicable

interferons

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2,Phase 1,Early Phase 1

Mitomycins

Phase 3,Phase 2,Phase 1,Early Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Alkylating Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1,Early Phase 1

Gastrointestinal Agents

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Central Nervous System Depressants

Phase 3,Phase 2

Adjuvants, Anesthesia

Phase 3

Anesthetics, Intravenous

Phase 3

Analgesics, Opioid

Phase 3

Peripheral Nervous System Agents

Phase 3,Phase 2

Anesthetics, General

Phase 3

Analgesics

Phase 3,Phase 2

Narcotics

Phase 3

Adjuvants, Immunologic

Phase 3,Phase 1

Interferon Inducers

Phase 3

Cetuximab

Approved

Phase 2,Phase 1

205923-56-4

56842117 2333

Carboplatin

Approved

Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Ritonavir

Approved, Investigational

Phase 2

155213-67-5

392622

Indinavir

Approved

Phase 2

150378-17-9

5362440

Formaldehyde

Approved, Vet_approved

Phase 2

50-00-0

712

Cidofovir

Approved

Phase 2

113852-37-2

60613

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2,Phase 2

6055-19-2, 50-18-0

2907

Fludarabine

Approved

Phase 1, Phase 2,Phase 2

75607-67-9, 21679-14-1

30751

Aldesleukin

Approved

Phase 1, Phase 2,Phase 2

85898-30-2, 110942-02-4

Interventional clinical trials:

(show top 50) (show all 194)

#	Name	Status	NCT ID	Phase	Drugs
1	Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients	Unknown status	NCT02624349	Phase 4	Quadravalent human papillomavirus vaccine
2	Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer	Unknown status	NCT00274885	Phase 4	oxaliplatin
3	Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study	Recruiting	NCT01824537	Phase 4
4	Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines	Recruiting	NCT03180034	Phase 4
5	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Unknown status	NCT00003652	Phase 3	cisplatin;fluorouracil
6	Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer	Completed	NCT00025090	Phase 3	cisplatin;fluorouracil;mitomycin C
7	Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Completed	NCT00003596	Phase 3	cisplatin;fluorouracil;mitomycin C
8	Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia	Completed	NCT01164722	Phase 3
9	An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)	Completed	NCT00090285	Phase 3
10	Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)	Completed	NCT01651949	Phase 3
11	Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer	Completed	NCT00075868	Phase 3	octreotide acetate
12	Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women	Completed	NCT01461096	Phase 3
13	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
14	Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions	Recruiting	NCT02135419	Phase 3	imiquimod;fluorouracil
15	Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy	Recruiting	NCT02369939	Phase 3	Mitomycin C;5-Fluorouracil
16	Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery	Recruiting	NCT02997553	Phase 3	Indocyanine green;Technetium99
17	Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients	Enrolling by invitation	NCT02526953	Phase 3	Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
18	Immunogenicity From 1 Dose of Bivalent HPV Vaccine in Girls to 3 Doses of Quadrivalent Vaccine in Women: the PRIMAVERA-ESCUDDO Trial	Not yet recruiting	NCT03728881	Phase 3
19	Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer	Terminated	NCT00068744	Phase 2, Phase 3	cisplatin;fluorouracil;mitomycin C
20	Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer	Unknown status	NCT00955240	Phase 2	cisplatin;fluorouracil
21	International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel	Unknown status	NCT02051868	Phase 2	Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
22	A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy	Unknown status	NCT00754078	Phase 2
23	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases	Unknown status	NCT00637637	Phase 2	indinavir sulfate;ritonavir
24	Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer	Completed	NCT00324415	Phase 2	cisplatin;fluorouracil
25	SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia	Completed	NCT00052897	Phase 1, Phase 2
26	Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer	Completed	NCT00423293	Phase 2	fluorouracil;mitomycin C
27	Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Completed	NCT00093379	Phase 2	Capecitabine;Oxaliplatin
28	Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus	Completed	NCT00550589	Phase 2	cidofovir
29	Vectibix for the Treatment of Anal Cancer	Completed	NCT01285778	Phase 2	panitumumab, mytomicin C, 5-FU, radiation
30	Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream	Completed	NCT00622440	Phase 2	AIJP (Arnebia Indigo Jade Pearl);Placebo
31	Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men	Completed	NCT00428285	Phase 2
32	Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males	Completed	NCT01209325	Phase 2
33	Erlotinib in Treating Patients With Advanced Kidney Cancer	Completed	NCT00045487	Phase 2	OSI-774
34	A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.	Completed	NCT01941966	Phase 2	Capecitabine;Mitomycins
35	T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers	Completed	NCT02280811	Phase 1, Phase 2	Fludarabine;Cyclophosphamide;Aldesleukin
36	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers	Completed	NCT01585428	Phase 2	Fludarabine;Cyclophosphamide;Aldesleukin
37	[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers	Completed	NCT01717391	Phase 2	fluorothymidine F 18
38	Oral Rigosertib for Squamous Cell Carcinoma	Completed	NCT01807546	Phase 2	rigosertib
39	Pembrolizumab in Refractory Metastatic Anal Cancer	Recruiting	NCT02919969	Phase 2	Pembrolizumab
40	Proton Therapy in Reducing Toxicity in Anal Cancer	Recruiting	NCT03018418	Phase 2	Chemotherapy
41	Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer	Recruiting	NCT02865135	Phase 1, Phase 2	DPX-E7 vaccine
42	Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer	Recruiting	NCT03381352	Phase 2	Capecitabine;Mitomycin C
43	A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma	Recruiting	NCT03519295	Phase 2	MPDL3280A;mDCF
44	Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer	Recruiting	NCT03233711	Phase 2
45	VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2	Recruiting	NCT03499795	Phase 2
46	LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer	Recruiting	NCT03690921	Phase 2	Cisplatin;Fluorouracil
47	M7824 in Subjects With HPV Associated Malignancies	Recruiting	NCT03427411	Phase 2	M7824
48	Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life	Recruiting	NCT02701088	Phase 2	5Fluorouracile and Mitomycin-C
49	A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand	Recruiting	NCT03302858	Phase 2
50	Avelumab With Valproic Acid in Virus-associated Cancer	Recruiting	NCT03357757	Phase 2	Valproic Acid

Search NIH Clinical Center for Anus Cancer

Cochrane evidence based reviews: anus neoplasms

Sources

Genetic Tests for Anus Cancer

Sources

Anatomical Context for Anus Cancer

MalaCards organs/tissues related to Anus Cancer:

⁴¹

Testes, Lymph Node, Skin, Colon, Liver, Bone, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Anus Cancer:

¹⁹

The Anus

Sources

Publications for Anus Cancer

Articles related to Anus Cancer:

(show top 50) (show all 780)

#	Title	Authors	Year
1	HPV-Associated Anal Cancer in the HIV/AIDS Patient. ( 30523625 )	Wang CJ...Palefsky JM	2019
2	Reduction in social activities mediates the relationship between diarrhea and distress in rectal/anal cancer survivors. ( 28665010 )	Benedict C...Nelson CJ	2018
3	Transperineal retropubic approach in total pelvic exenteration for advanced and recurrent colorectal and anal cancer involving the penile base: technique and outcomes. ( 30306276 )	Mehta AM...Jenkins JT	2018
4	Anal cancer in high-income countries: Increasing burden of disease. ( 30339668 )	Kang YJ...Canfell K	2018
5	Recent advances in the management of anal cancer. ( 30345012 )	Symer MM...Yeo HL	2018
6	Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States. ( 30362917 )	Wu CF...Lairson DR	2018
7	Experimental and investigational drugs for the treatment of anal cancer. ( 30381968 )	Jacome AA...Eng C	2018
8	ASO Author Reflections: Salvage Surgery for Anal Cancer. ( 30414037 )	Hagemans JAW	2018
9	Anal Cancer: Putting Health-Related Quality of Life at the Forefront. ( 30415785 )	Sodergren SC...EORTC Quality of Life Group	2018
10	Association of anal symptoms with anal high grade squamous intraepithelial lesions (HSIL) among men who have sex with men: Baseline data from the study of the prevention of anal cancer (SPANC). ( 30439602 )	Goddard SL...Study for the Prevention of Anal Cancer (SPANC) Research Team	2018
11	Accuracy of Anal Cytology for Diagnostic of Precursor Lesions of Anal Cancer: Systematic Review and Meta-analysis. ( 30451747 )	Gon?alves JCN...da Rosa MI	2018
12	Dosimetric comparison of different radiation techniques (IMRT vs. 3-dimensional) of the "true" (deep) ano-inguinal lymphatic drainage of anal cancer patients. ( 30466454 )	Dapper H...Habermehl D	2018
13	Effect of an Educational Video to Increase Calls and Screening into an Anal Cancer Clinical Trial Among HIV+ Hispanics in PR: Results from a Randomized Controlled Behavioral Trial. ( 30467711 )	Ortiz AP...Col?n-L?pez V	2018
14	Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy. ( 30482037 )	Ghareeb A...Jha M	2018
15	Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. ( 30484384 )	Koerber SA...Sterzing F	2018
16	A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. ( 30507470 )	Fish R...Renehan AG	2018
17	Incorporating digital anorectal examinations for anal cancer screening into routine HIV care for men who have sex with men living with HIV: a prospective cohort study. ( 30516346 )	Ong JJ...Fairley CK	2018
18	Factors associated with self-reported anal cancer screening history in men who have sex with men. ( 30517839 )	Hicks JT...Nyitray AG	2018
19	Sociodemographic Predictors of Anal Cancer Screening and Follow-up in Human Immunodeficiency Virus-Infected Individuals. ( 28723723 )	Wells JS...Watkins Bruner D	2018
20	A phase II clinical study to assess the feasibility of self and partner anal examinations to detect anal canal abnormalities including anal cancer. ( 28835533 )	Nyitray AG...Chiao EY	2018
21	Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer. ( 28856848 )	Arcadipane F...Ricardi U	2018
22	Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy for anal cancer. ( 28884454 )	Tom A...Goodman KA	2018
23	The volume of PET-defined, active bone marrow spared predicts acute hematologic toxicities in anal cancer patients receiving concurrent chemoradiotherapy. ( 28903619 )	Freese C...Kharofa J	2018
24	Differences in the Immune Microenvironment of Anal Cancer Precursors by HIV Status and Association With Ablation Outcomes. ( 28968881 )	Liu Y...Sigel K	2018
25	Effect of CD4 Count on Treatment Toxicity and Tumor Recurrence in Human Immunodeficiency Virus-Positive Patients With Anal Cancer. ( 29102276 )	Bryant AK...Murphy JD	2018
26	Anal Cancer Risk Among People With HIV Infection in the United States. ( 29140774 )	Col?n-L?pez V...Engels EA	2018
27	The importance of HPV16 in anal cancer prevention. ( 29158103 )	Wieland U...Kreuter A	2018
28	Barriers to participation in a sexual health intervention for men following treatment for rectal and anal cancer. ( 29172234 )	Shaffer KM...DuHamel KN	2018
29	High prevalence and incidence of HPV-related anal cancer precursor lesions in HIV-positive women in the late HAART era. ( 29208455 )	Hidalgo-Tenorio C...Pasquau J	2018
30	Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer. ( 29217122 )	Sodergren SC...EORTC Quality of Life Group	2018
31	Dosimetric quantification of the incidental irradiation of the 'true' (deep) ano-inguinal lymphatic drainage of anal cancer patients not described in conventional contouring guidelines. ( 29297232 )	Dapper H...Habermehl D	2018
32	Target volume motion during anal cancer image guided radiotherapy using cone-beam computed tomography. ( 29393674 )	Brooks CJ...Tait DM	2018
33	Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy. ( 29404766 )	Hocquelet A...Vendrely V	2018
34	Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients. ( 29441419 )	De Bari B...Zilli T	2018
35	Anal sphincter dysfunction in patients treated with primary radiotherapy for anal cancer: a study with the functional lumen imaging probe. ( 29447025 )	Haas S...Krogh K	2018
36	Primary Care Provider Practices and Perceptions Regarding HPV Vaccination and Anal Cancer Screening at a Boston Community Health Center. ( 29480339 )	Apaydin KZ...Keuroghlian AS	2018
37	Deviations From Standard Chemoradiation Among Early-Stage Anal Cancer Patients. ( 29485073 )	Churilla TM...Meyer JE	2018
38	HIV-positive MSM's knowledge of HPV and anal cancer self-sampling: A scoping review. ( 29507499 )	Poon MKL...Vahabi M	2018
39	Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy. ( 29522569 )	Foster CC...Liauw S	2018
40	Impact of socioeconomic status on survival for patients with anal cancer. ( 29527660 )	Lin D...Becker DJ	2018
41	Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC). ( 29566456 )	Fish R...Williamson PR	2018
42	Outcome of surgery for recurrent anal cancer: results from a tertiary referral centre. ( 29573536 )	Bignell M...Branagan G	2018
43	Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT. ( 29594584 )	Dell'Acqua V...Jereczek-Fossa BA	2018
44	Treatment of Anal Cancer Pain-A Case Report. ( 29608933 )	Ali SK...Abdulkarim S	2018
45	E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line. ( 29624161 )	Wechsler EI...Palefsky JM	2018
46	Risk of Anal Cancer in Women With a Human Papillomavirus-Related Gynecological Neoplasm: Puerto Rico 1987-2013. ( 29649025 )	Acevedo-Font?nez AI...Ortiz AP	2018
47	Salvage Abdominoperineal Resection for Squamous Cell Anal Cancer: A 30-Year Single-Institution Experience. ( 29691737 )	Hagemans JAW...Burger JWA	2018
48	Anal cytological lesions and HPV infection in individuals at increased risk for anal cancer. ( 29694716 )	Don? MG...Giuliani M	2018
49	Abnormal neuronal response to rectal and anal stimuli in patients treated with primary radiotherapy for anal cancer. ( 29706461 )	Haas S...Christensen P	2018
50	Limitations of the National Cancer Data Base to Evaluate Early-Stage Anal Cancer Treatment Outcomes. ( 29710110 )	Renehan AG...Sebag-Montefiore D	2018

Sources

Genes for Anus Cancer

Genes related to Anus Cancer (0 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SERPINB3	Serpin Family B Member 3	Protein Coding	21.77	DISEASES inferred ¹⁵ ¹⁵
2	SLC14A2	Solute Carrier Family 14 Member 2	Protein Coding	21.15	DISEASES inferred ¹⁵ ¹⁵
3	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	20.8	DISEASES inferred ¹⁵ ¹⁵
4	RORC	RAR Related Orphan Receptor C	Protein Coding	18.41	DISEASES inferred ¹⁵ ¹⁵
5	KRT7	Keratin 7	Protein Coding	18.25	DISEASES inferred ¹⁵ ¹⁵
6	IARS	Isoleucyl-TRNA Synthetase	Protein Coding	18.2	DISEASES inferred ¹⁵ ¹⁵
7	CDX2	Caudal Type Homeobox 2	Protein Coding	17.8	DISEASES inferred ¹⁵ ¹⁵
8	KRT5	Keratin 5	Protein Coding	17.24	DISEASES inferred ¹⁵ ¹⁵
9	SMUG1	Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1	Protein Coding	15.77	DISEASES inferred ¹⁵
10	CD6	CD6 Molecule	Protein Coding	15.52	DISEASES inferred ¹⁵
11	DCXR	Dicarbonyl And L-Xylulose Reductase	Protein Coding	15.37	DISEASES inferred ¹⁵
12	SETD1A	SET Domain Containing 1A	Protein Coding	15.13	DISEASES inferred ¹⁵

Sources

Variations for Anus Cancer

Sources

Expression for Anus Cancer

Search GEO for disease gene expression data for Anus Cancer.

Sources

Pathways for Anus Cancer

Sources

GO Terms for Anus Cancer

Sources

Sources for Anus Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia